Discrete Assay for Integrated HPV DNA in Cervical Cells

宫颈细胞中整合 HPV DNA 的离散检测

• 批准号: 6658089
• 负责人: PHILLIP T MOEN
• 金额: $ 39.72万
• 依托单位: ONE CELL SYSTEMS, INC
• 依托单位国家: 美国
• 财政年份: 2000
• 资助国家: 美国
• 起止时间: 2000-09-01 至 2005-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6658089
• 关键词: cell line; cervix; cervix neoplasms; clinical research; communicable disease diagnosis; cytodiagnosis; diagnosis design /evaluation; female; human papillomavirus; human tissue; in situ hybridization; neoplasm /cancer genetics; neoplastic process; polymerase chain reaction; tissue /cell preparation; virus DNA

DESCRIPTION (provided by applicant): Human papillomavirus (HPV) is implicated as the primary cause of cervical cancer. Although assays that reliably detect HPV are available, their prognostic value for predicting progression to cervical cancer remains controversial, underscoring the need for assays with improved prognostic value. This Phase II SBIR will develop a novel method for detecting integrated HPV DNA in cervical cells. Oncogenic HPV DNA integration into the host genome is a common occurrence in cervical cancers and dysplasias, and assays targeting this event may have high clinical value. Detection of integrated HPV DNA, however, is complicated by the frequent co-existence of episomal viral DNA. Using model cell lines which contain both episomal and integrated HPV DNA, and analytical methods such as in situ hybridization and PCR, Phase I research successfully detected integrated HPV DNA. Phase II research will optimize this approach for use with clinical samples and current liquid-based cytology methods. In contrast to conventional HPV tests, which identify viral types, this assay detects viral integration and targets a wider range of viral types, increasing assay sensitivity. PROPOSED COMMERCIAL APPLICATIONS: This screening method for integrated HPV DNA in cervical cells will facilitate diagnosis of cervical cancer and early treatment, reducing mortality rates.

描述（由申请人提供）：